​​​
  1. Lupin arm gets USFDA nod to market generic Zyvox tablets

Lupin arm gets USFDA nod to market generic Zyvox tablets

The company's US-based subsidiary Gavis Pharmaceuticals has received final approval for its linezolid tablets in 600 mg strength from the US Food and Drug Administration (USFDA), Lupin said in a BSE filing.

By: | New Delhi | Published: August 24, 2016 4:59 PM
The company's US-based subsidiary Gavis Pharmaceuticals has received final approval for its linezolid tablets in 600 mg strength from the US Food and Drug Administration (USFDA), Lupin said in a BSE filing.  (Reuters) The company’s US-based subsidiary Gavis Pharmaceuticals has received final approval for its linezolid tablets in 600 mg strength from the US Food and Drug Administration (USFDA), Lupin said in a BSE filing. (Reuters)

Drug major Lupin today said its subsidiary Gavis Pharmaceuticals has received approval from the US health regulator to market generic linezolid tablets used for treating bacterial infection in the American market.

The company’s US-based subsidiary Gavis Pharmaceuticals has received final approval for its linezolid tablets in 600 mg strength from the US Food and Drug Administration (USFDA), Lupin said in a BSE filing.

Gavis’ product is a generic version of Pharmacia and Upjohn company’s Zyvox tablets, which is indicated in adults and children for treatment of certain infections caused by susceptible gram-positive bacteria.

As per IMS MAT June sales data, Zyvox tablets had US sales of USD 273.6 million. The stock ended 2.20 per cent down at Rs 1,520.50 on BSE.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Go to Top